From Synaptic Dysfunction to Memory Recovery: Ampakine Compounds as Potential Therapeutic Agents for Alzheimer's Disease
Küçük Resim Yok
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Atatürk Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Alzheimer's disease, a profoundly impactful neurodegenerative condition, manifests as the progressive deterioration of memory and cognitive functions. Studies have shown that memory decline is associated with a decrease in the rapid transmission of excitatory signals between neurons. The limited research on the positive impact of AMPA receptor modulation has prompted the exploration of Ampakine compounds. Ampakines enhance long-term potentiation (LTP) by activating receptors, which exists in a crucial role in memory preservation. The ability of ampakine compounds to bind to AMPA receptors and increase the expression of neurotrophic factors, such as BDNF, is believed to mitigate LTP impairment. Recent studies have demonstrated that certain ampakine compounds can enhance consciousness and memory storage by promoting the production of various neurotrophins, particularly BDNF and NGF. Previous research has shown that neurotrophins contribute to synaptogenesis, the formation of new connections between neurons, primarily through dendritic spines. Increasing synaptogenesis via dendritic spines positively impacts signal transmission and retention by strengthening neuronal connections. This review highlights the potential of ampakine compounds such as pesampator and hydroflumetazide to enhance synaptic interactions, alleviate symptoms of Alzheimer's disease, and specifically address memory loss through their effects on neurotrophins.
Açıklama
Anahtar Kelimeler
Pharmaceutical Sciences, Eczacılık Bilimleri
Kaynak
Recent Trends in Pharmacology
Recent Trends in Pharmacology
Recent Trends in Pharmacology
WoS Q Değeri
Scopus Q Değeri
Cilt
1
Sayı
3
